VB TECH Virtual Brain Technologies

VB-Tech operates at the intersection of biotechnology, healthcare, and life science, applying brain simulation to neurological interventions. Its stated approach combines neuroimaging, electrophysiology, and brain-connectivity data to create personalized functional brain simulations. The company's first named clinical application, VEP – Virtual Epileptic Patient™, targets drug-resistant epilepsy, a focused use case within the broader digital health and precision-medicine landscape. The website describes a clinically validated modeling framework, while also noting that VEP is undergoing clinical and regulatory validation; that distinction matters because it does not establish routine clinical use or regulatory clearance. The company identifies Virtual Brain technology and BrainXplore Hub in its product and technology portfolio. Its discernible point of distinction is the use of individualized brain models for intervention support, rather than a general-purpose healthcare software proposition. With a reported team size of 1–10 and one disclosed seed round, VB-Tech appears to be an early-stage specialist; evidence on market share, customer base, and comparative clinical outcomes is limited.

VB-Tech was founded in 2022 and has developed around a specialized proposition: personalized digital brain twins for neurological interventions. Its first recorded financing inflection point was a €500,000 seed round, equivalent to $519,167, announced on Jan 6, 2025 and led by Rise Partners. A second visible inflection point came on Sep 29, 2026, when coverage described a functional digital twin of the human brain developed by the Marseille startup. On the product side, VEP – Virtual Epileptic Patient™ applies the modeling approach to drug-resistant epilepsy, and the company says clinical and regulatory validation is ongoing. The trajectory therefore shows movement from founding to seed financing and public visibility for its brain-simulation work, with clinical validation an important next development stage. Commercial traction, regulatory milestones, follow-on financing, and hiring plans remain unclear.